Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma
Table 3
Clinical and pathological features of T1 lung adenocarcinoma patients with EGFR exon 19 deletion or exon 21 point mutations. Where appropriate, data are n (%).
Characteristics
Exon 19 ()
Exon 21 ()
Age, mean y (range)
59.7 ± 10.7 (30–80)
61.2 ± 9.4 (28–84)
0.324a
Sex
Male
24 (35.8)
43 (64.2)
0.263b
Female
40 (28.2)
102 (71.8)
Smoking
Nonsmoker
50 (28.6)
125 (71.4)
0.158b
Current/former
14 (41.2)
20 (58.8)
CEA
<2.12 IU/mL
42 (33.9)
82 (66.1)
0.218b
≥2.12 IU/mL
22 (25.9)
63 (74.1)
Type of surgery
Lobectomy
48 (31.6)
104 (68.4)
0.737b
Limited
16 (28.1)
41 (71.9)
Tumour size
pT1a
16 (24.2)
50 (75.8)
0.231b
pT1b
32 (31.1)
71 (68.9)
pT1c
16 (40.0)
24 (60.0)
Histology
AIS
6 (20.0)
24 (80.0)
0.267b
MIA
15 (27.8)
39 (72.2)
IAC
43 (34.4)
82 (65.6)
IAC subtype ()
Lepidic
3 (10.7)
25 (89.3)
0.022c
Acinar
16 (40.0)
24 (60.0)
Papillary
23 (41.8)
32 (58.2)
Solid
1 (50.0)
1 (50.0)
Pleural invasion
No
54 (29.3)
130 (70.7)
0.278b
Yes
10 (40.0)
15 (60.0)
Lymph nodes
pN0
59 (30.6)
134 (69.4)
0.955b
pN1 or 2
5 (31.3)
11 (68.7)
Pathological stage
0
6 (20.7)
24 (79.3)
0.216b
IA
43 (30.1)
99 (69.9)
IB
10 (47.6)
11 (52.4)
IIA, IIB, IIIA
5 (31.3)
11 (68.7)
CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma. by at-test, bPearson’s chi-squared test, and cFisher’s exact test.
